Next Article in Journal
Ganoderma formosanum Exopolysaccharides Inhibit Tumor Growth via Immunomodulation
Previous Article in Journal
Macrophage-Dependent Interleukin-6-Production and Inhibition of IK Contributes to Acquired QT Prolongation in Lipotoxic Guinea Pig Heart
Previous Article in Special Issue
Insights on Metabolic Reprogramming and Its Therapeutic Potential in Acute Leukemia

Myelodysplastic Syndromes and Metabolism

Medical Department I, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany
German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
National Center for Tumor Diseases, Partner Site Dresden and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus Dresden, 01307 Dresden, Germany
Authors to whom correspondence should be addressed.
Academic Editor: Matilde Yung Follo
Int. J. Mol. Sci. 2021, 22(20), 11250;
Received: 10 September 2021 / Revised: 6 October 2021 / Accepted: 14 October 2021 / Published: 19 October 2021
(This article belongs to the Special Issue Metabolism and Leukemia: From Biology to Therapies)
Myelodysplastic syndromes (MDS) are acquired clonal stem cell disorders exhibiting ineffective hematopoiesis, dysplastic cell morphology in the bone marrow, and peripheral cytopenia at early stages; while advanced stages carry a high risk for transformation into acute myeloid leukemia (AML). Genetic alterations are integral to the pathogenesis of MDS. However, it remains unclear how these genetic changes in hematopoietic stem and progenitor cells (HSPCs) occur, and how they confer an expansion advantage to the clones carrying them. Recently, inflammatory processes and changes in cellular metabolism of HSPCs and the surrounding bone marrow microenvironment have been associated with an age-related dysfunction of HSPCs and the emergence of genetic aberrations related to clonal hematopoiesis of indeterminate potential (CHIP). The present review highlights the involvement of metabolic and inflammatory pathways in the regulation of HSPC and niche cell function in MDS in comparison to healthy state and discusses how such pathways may be amenable to therapeutic interventions. View Full-Text
Keywords: myelodysplastic syndromes; metabolism; inflammation myelodysplastic syndromes; metabolism; inflammation
Show Figures

Figure 1

MDPI and ACS Style

Balaian, E.; Wobus, M.; Bornhäuser, M.; Chavakis, T.; Sockel, K. Myelodysplastic Syndromes and Metabolism. Int. J. Mol. Sci. 2021, 22, 11250.

AMA Style

Balaian E, Wobus M, Bornhäuser M, Chavakis T, Sockel K. Myelodysplastic Syndromes and Metabolism. International Journal of Molecular Sciences. 2021; 22(20):11250.

Chicago/Turabian Style

Balaian, Ekaterina, Manja Wobus, Martin Bornhäuser, Triantafyllos Chavakis, and Katja Sockel. 2021. "Myelodysplastic Syndromes and Metabolism" International Journal of Molecular Sciences 22, no. 20: 11250.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop